Antiviral agents for the treatment, control and prevention of infections by coronaviruses
AssigneeSequoia Pharmaceuticals, Inc.
InventorsJohn Erickson, Abelardo Silva
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infaction, in a subject, such as a human subject.
Claims20
An antiviral peptide having between 7 and 50 amino acids, wherein said peptide exhibits antiviral activity against a coronavirus, and where said peptide contains a sequence comprising at least 7 contiguous amino acids from one of the following sequences:
- (SEQ ID NO:
- 1)
- DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK;
- (SEQ ID NO:
- 2)
- QIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLT;
- (SEQ ID NO:
- 3)
- ESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISS;
- (SEQ ID NO:
- 4)
- GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAE;
- and
- (SEQ ID NO:
- 5)
- RLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDF.
An antiviral peptide having between 7 and 50 amino acids, wherein said peptide exhibits antiviral activity against a coronavirus, and wherein said peptide has the structure:
- B-X-Z,
- where B is an amino acid sequence containing up to about 43 amino acids, or B is an amino group, an acetyl group, a 9-fluorenylmethoxy-carbonyl group, a hydrophobic group, or a macromolecule carrier group, or B is a carrier protein, in which case B may contain more than 8 sequence to said carrier protein;
- Z is an amino acid sequence containing up to about 43 amino acids, or Z comprises a carboxyl group, an amindo group, a hydrophobic group, or a macromolecular carrier group, or Z is a carrier protein, such as HSA, in which case Z may contain more than 8 amino acids, and may also comprises a linker peptide sequence that connects the antiviral sequence to said carrier protein;
- wherein when considered together B and Z must contain at least 8 amino acids between the B and Z group;
- and wherein X is a peptide sequence comprising at least 7 contiguous amino acids from one of the following sequences:
- (SEQ ID NO:
- 181)
- VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK;
- (SEQ ID NO:
- 2)
- QIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLT;
- (SEQ ID NO:
- 3)
- ESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISS;
- (SEQ ID NO:
- 4)
- GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAE;
- and
- (SEQ ID NO:
- 5)
- RLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDF.
An antiviral peptide having between 7 and 50 amino acids, wherein said peptide exhibits antiviral activity against a coronavirus, and wherein said peptide comprises a sequence that exhibits identity in any two of the seven positions of a contiguous heptapeptide, wherein said contiguous heptapeptide comprises 7 contiguous amino acids from one of the following sequences:
- (SEQ ID NO:
- 181)
- VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK;
- (SEQ ID NO:
- 2)
- QIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLT;
- (SEQ ID NO:
- 3)
- ESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISS;
- (SEQ ID NO:
- 4)
- GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAE;
- and
- (SEQ ID NO:
- 5)
- RLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDF.
An antiviral peptide having between 7 and 50 amino acids, wherein said peptide exhibits antiviral activity against a coronavirus, and wherein said peptide contains a sequence comprising at least 7 contiguous amino acids from the sequence:
- (SEQ ID NO:
- 1)
- DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK;
- wherein the amino acids at bold letter positions can be substituted with an amino acid selected from the group consisting of I, L, V, W, Y, F, N, Q, S, T, D, E, G, H, and M, and wherein amino acids in non-bold positions can be any amino acid except proline.
Dependencies are inferred from the claim text.